부산대학교 도서관

With the clinical success of immune checkpoint inhibitors (ICIs), cancer immunotherapy has become an important pillar of cancer treatment in various types of cancer. However, more than half of patients fail to respond to ICIs, even in combination, uncovering a limited window of clinical responses. Therefore, it is essential to develop more effective cancer immunotherapies and to define biomarkers for stratifying responders and nonresponders by exploring the immunological landscape in the tumor microenvironment (TME). It has become clear that differences in immune responses in the TME determine the clinical efficacy of cancer immunotherapies. Additionally, gene alterations in cancer cells contribute to the development of the immunological landscape, particularly immune suppression in the TME. Therefore, integrated analyses of immunological and genomic assays are key for understanding diverse immune suppressive mechanisms in the TME. Developing novel strategies to control immune suppression in the TME from the perspective of immunology and the cancer genome is crucial for effective cancer immunotherapy (immune-genome precision medicine). Keywords: cancer immunotherapy, immune checkpoint inhibitors, tumor microenvironment, immune suppression, immune-genome precision medicine
1. Introduction Currently, approximately half of Japanese people will develop malignant tumors (cancer) in their lifetime (https://ganjoho.jp/public/qa_links/report/statistics/2023_en.html, in Japanese). Furthermore, cancer accounts for approximately 20% of all deaths in Japan. [...]